A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.

NCT05877924 | Recruiting Phase 1

• 1 other identifier: NBL-020-001
• Study Type: interventional
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the safety and tolerability of NBL-020 injection in subjects with advanced malignant tumors, and determine the dose limiting toxicity (DLT), maximum tolerable dose (MTD) (if any), recommended phase II dose (RP2D), and dosing regimen of NBL-020.

Conditions

Advanced Malignant Tumors

Outcome Measures

Primary Outcomes (1)

• The occurrence of all adverse events (AEs) and severe adverse events (SAEs).

  adverse events (AEs) and severe adverse events (SAEs)

  From the first administration to 30 days after the end of the last administration, up to approximately 2 years

Secondary Outcomes (14)

• Cmax

  14 days

• AUC0-t

  14 days

• AUC0-inf

  14 days

• Tmax

  14 days

• t1/2

  14 days

Study Arms (1)

NBL-020

EXPERIMENTAL

Dose increasing study: The initial dose for the dose escalation study is 0.1 mg/kg administered once every 3 weeks (Q3W), with a pre-set maximum escalation dose of 30 mg/kg Q3W. Dose expansion study: Based on the results of the dose escalation study, the dosage for the dose extension study will be determined through joint discussion between the sponsor and the investigators.

Drug: NBL-020 for Injection

Interventions

NBL-020 for Injection DRUG

NBL-020 for Injection, Q3W, i.v.

NBL-020

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Those who are 18 years old or older (based on the date of signing the informed consent form) and voluntarily sign the informed consent form;
• For malignant tumors confirmed by histology or cytology, only solid tumor subjects were included in dose escalation study. In addition to solid tumors, additional skin T-cell lymphoma subjects could be considered in dose expansion study;
• Must be willing to provide tumor tissue samples that can meet the requirements of biomarker testing (fresh biopsy tissue is preferred; if fresh tissue cannot be provided, tumor tissue samples within 2 years can be provided), and tumor samples will be tested by the central laboratory. If tumor tissue does not meet the testing requirements, additional biopsy may be required;
• If the standard treatment fails or toxicity is intolerable, or there is no standard treatment, the enrolled subjects must fully recover from previous treatment, with an AE level of 0-1 (except for alopecia, pigmentation, or other toxicity that the researcher believes is not a safety risk to the subjects);
• For subjects with solid tumor, there is at least one measurable lesion that meets the RECIST 1.1 standard at the baseline (the measurable lesion area has not received radiotherapy in the past, or there is evidence that the lesion has unequivocal progressed after radiotherapy);
• ECOG PS score 0-1 points;
• Expected survival time ≥ 3 months (12 weeks);
• Good organ function (no blood transfusion or growth factor support treatment received within 2 weeks before blood collection for relevant examinations), including:
• Absolute value of neutrophils (ANC) ≥ 1.5 × 10\^9/L；
• Hemoglobin (Hb) ≥ 90 g/L;
• Platelets ≥ 100 × 10\^9 /L;
• Creatinine ≤ 1.5 times the upper limit of normal value (ULN) or creatinine clearance rate ≥ 50 mL/min (Cockcroft Fault formula);
• Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert's syndrome）;
• Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) ≤ 2.5 × ULN (≤ 5 × ULN for subjects with liver metastasis);
• Coagulation function: activated partial thromboplastin time(APTT), international standardized ratio (INR) ≤ 1.5 × ULN.

You may not qualify if:

• Subjects with a history of severe allergies to monoclonal antibodies;
• Active pia mater lesions or uncontrolled brain metastases exist. Subjects with suspected or confirmed brain metastasis can be enrolled as long as they are asymptomatic and do not require treatment (such as radiotherapy, surgery, or corticosteroid therapy) to control the symptoms of brain metastasis. For subjects with brain metastasis requiring treatment, their symptoms remain stable (without hormone maintenance treatment, without symptoms of brain metastasis) for 2 weeks after treatment, and they can be enrolled.
• Subjects with active autoimmune diseases or a history of autoimmune diseases, but with the following diseases are allowed to be included in the study: well controlled type I diabetes, well controlled hypothyroidism only requiring hormone replacement treatment, skin diseases without systemic treatment (such as vitiligo, psoriasis or alopecia), or subjects who are expected to have no relapse under the condition of no external trigger factors;
• Having a history of primary immunodeficiency, a history of allogeneic organ transplantation, or a history of allogeneic hematopoietic stem cell transplantation;
• Chronic hepatitis B (HBsAg and/or HBcAb positive but HBV DNA\<2000 IU/mL can be included), chronic hepatitis C (HCV antibody positive but HCV RNA negative can be included), and HIV antibody positive;
• The toxicity of previous anti-tumor treatments has not returned to ≤ Grade 1 (except for alopecia, pigmentation, or other toxicity that the researchers believe is not a safety risk to the subjects);
• Have a history of serious cardiovascular disease, including but not limited to:
• Serious cardiac rhythm or conduction abnormalities, including but not limited to ventricular arrhythmias requiring clinical intervention, third degree atrioventricular block, within 6 months prior to the first dose of the investigational drug;
• Have a history of myocardial infarction, unstable angina, angioplasty, or coronary artery bypass surgery within 6 months before the first dose of the experimental drug;
• Heart failure, classified as Grade Ш or above by the New York Heart Association (NYHA);
• Subjects with prolonged QT/QTc interval in the screening period electrocardiogram);
• During the screening, echocardiography showed left ventricular ejection fraction (LVEF)\<50%;
• Poor control of hypertension (screening period systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg);
• Uncontrollable serous cavity effusion that requires frequent drainage or medical intervention (such as pleural effusion, abdominal effusion, pericardial effusion, etc., which requires additional intervention within 2 weeks after the intervention, excluding exfoliative cytology testing of the exudate) within 7 days before the first dose of the experimental drug;
• Severe or active infections (including tuberculosis infections) that require systemic antibacterial, antifungal, or antiviral treatment within 14 days before the first use of the experimental drug, except for subjects with viral hepatitis receiving antiviral treatment;

Sponsors & Collaborators

• NovaRock Biotherapeutics, Ltd: lead

Study Sites (1)

Wu Yilong

Guanzhou, Guangdong, China

RECRUITING

MeSH Terms

Interventions

Injections

Intervention Hierarchy (Ancestors)

Drug Administration Routes; Drug Therapy; Therapeutics

Study Officials

• Yilong Wu

  Guangdong Provincial People's Hospital, Guangzhou City, Guangdong Province, China

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yilong Wu

CONTACT

021-38804518-22132; Syylwu@live.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 18, 2023
• First Posted: May 26, 2023
• Study Start: August 15, 2023
• Primary Completion: August 1, 2025
• Study Completion (Estimated): December 1, 2026
• Last Updated: March 26, 2024

Record last verified: 2023-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)